Monthly
US$200
Billed every month
Acarbose Tablets(阿卡波糖片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders24View records ↓
Under-review filings3View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers30View records ↓
API companies with A status14View records ↓
Chemical-drug catalogue
Loaded records: 24 holders; 2 in the quality-and-efficacy consistency-evaluation category, and 21 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 上海现代制药股份有限公司 | 上海现代制药股份有限公司 | 国药准字H20265268 | 2026/07/21 | 0.1g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海现代制药股份有限公司 | 上海现代制药股份有限公司 | 国药准字H20265267 | 2026/07/21 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省宝诺医药研发有限公司 | 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 2025/12/09 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东普瑞曼药业有限公司 | 山东普瑞曼药业有限公司 | 国药准字H20255254 | 2025/08/26 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 恒昌（广州）新药研究有限公司 | 南京海纳制药有限公司 | 国药准字H20253463 | 2025/02/25 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 生达化学制药股份有限公司 | 生达化学制药股份有限公司二厂 | 国药准字HC20240007 | 2024/10/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州民生药业股份有限公司 | 杭州民生药业股份有限公司 | 国药准字H20244515 | 2024/07/30 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江京新药业股份有限公司 | 浙江京新药业股份有限公司 | 国药准字H20244564 | 2024/07/30 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江京新药业股份有限公司 | 浙江京新药业股份有限公司 | 国药准字H20244563 | 2024/07/30 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都恒瑞制药有限公司 | 成都恒瑞制药有限公司 | 国药准字H20243876 | 2024/06/04 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏德源药业股份有限公司 | 江苏德源药业股份有限公司 | 国药准字H20237040 | 2023/04/18 | 0.1g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 贵州天安药业股份有限公司 | 贵州天安药业股份有限公司 | 国药准字H20223652 | 2022/09/14 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20223134 | 2022/03/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆药友制药有限责任公司 | 重庆药友制药有限责任公司 | 国药准字H20223135 | 2022/03/16 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华润赛科药业有限责任公司 | 华润赛科药业有限责任公司 | 国药准字H20223141 | 2022/03/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江海正药业股份有限公司 | 浙江海正药业股份有限公司 | 国药准字H20227010 | 2022/01/30 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏德源药业股份有限公司 | 江苏德源药业股份有限公司 | 国药准字H20223062 | 2022/01/30 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 贵州圣济堂制药有限公司 | 贵州圣济堂制药有限公司 | 国药准字H20213948 | 2021/12/14 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药股份有限公司 | 山东鲁抗医药股份有限公司 | 国药准字H20213876 | 2021/11/17 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辽宁鑫善源药业有限公司 | 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 2021/08/25 | 50mg | Not stated by source | CDE |
| 辽宁鑫善源药业有限公司 | 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 2021/08/25 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江乐普药业股份有限公司 | 博瑞制药（苏州）有限公司 | 国药准字H20213222 | 2021/03/30 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南千金湘江药业股份有限公司 | 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 2021/01/19 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京博康健基因科技有限公司 | 北京博康健基因科技有限公司 | 国药准字H20203562 | 2020/11/10 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京博康健基因科技有限公司 | 北京博康健基因科技有限公司 | 国药准字H20203563 | 2020/11/10 | 100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江海正药业股份有限公司 | 浙江海正药业股份有限公司 | 国药准字H20203311 | 2020/07/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20203314 | 2020/07/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20193360 | 2019/12/06 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州中美华东制药有限公司 | 杭州中美华东制药有限公司 | 国药准字H20153002 | 2019/05/27 | 100mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 杭州中美华东制药有限公司 | 杭州中美华东制药有限公司 | 国药准字H20020202 | 2018/11/19 | 50mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 拜耳医药保健有限公司 | 国药准字H20010716 | 2001/11/05 | 0.1g | Other drug (其他药品) | CDE |
| — | 拜耳医药保健有限公司 | 国药准字H19990205 | 1999/09/03 | 50mg | Other drug (其他药品) | CDE |
| Bayer Vital GmbH | Bayer Pharma AG | H20130906 | 1994/12/09 | 50mg | Imported originator drug (进口原研药品) | CDE |
| Bayer Vital GmbH | Bayer Pharma AG | H20130907 | 1994/12/09 | 100mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 30 distinct approval numbers and 22 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 拜耳医药保健有限公司 | 国药准字H20010716 | 0.1g | Category A (甲) | XA10BFA025A001010100002 | NHSA |
| 北京博康健基因科技有限公司 | 国药准字H20203563 | 100mg | Category A (甲) | XA10BFA025A001010100024 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001010100062 | NHSA |
| 华润赛科药业有限责任公司 | 国药准字H20223141 | 50mg | Category A (甲) | XA10BFA025A001010100111 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20193360 | 50mg | Category A (甲) | XA10BFA025A001010100177 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20223134 | 50mg | Category A (甲) | XA10BFA025A001010101066 | NHSA |
| 成都恒瑞制药有限公司 | 国药准字H20243876 | 50mg | Category A (甲) | XA10BFA025A001010102031 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010102770 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20244515 | 50mg | Category A (甲) | XA10BFA025A001010104494 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20153002 | 100mg | Category A (甲) | XA10BFA025A001010104520 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203311 | 50mg | Category A (甲) | XA10BFA025A001010104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010104658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010104960 | NHSA |
| 贵州圣济堂制药有限公司 | 国药准字H20213948 | 50mg | Category A (甲) | XA10BFA025A001010105521 | NHSA |
| 双鹤天安药业(贵州)股份有限公司 | 国药准字H20223652 | 50mg | Category A (甲) | XA10BFA025A001010105530 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20223062 | 50mg | Category A (甲) | XA10BFA025A001010106632 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20213222 | 50mg | Category A (甲) | XA10BFA025A001010180081 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010181767 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20213876 | 50mg | Category A (甲) | XA10BFA025A001010183198 | NHSA |
| 恒昌(广州)新药研究有限公司 | 国药准字H20253463 | 50mg | Category A (甲) | XA10BFA025A001010183569 | NHSA |
| 山东普瑞曼药业有限公司 | 国药准字H20255254 | 50mg | Category A (甲) | XA10BFA025A001010184621 | NHSA |
| 拜耳医药保健有限公司 | 国药准字H20010716 | 0.1g | Category A (甲) | XA10BFA025A001010200002 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001010200062 | NHSA |
| 华润赛科药业有限责任公司 | 国药准字H20223141 | 50mg | Category A (甲) | XA10BFA025A001010200111 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20193360 | 50mg | Category A (甲) | XA10BFA025A001010200177 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20223134 | 50mg | Category A (甲) | XA10BFA025A001010201066 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010202770 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20153002 | 100mg | Category A (甲) | XA10BFA025A001010204520 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010204658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010204960 | NHSA |
| 贵州圣济堂制药有限公司 | 国药准字H20213948 | 50mg | Category A (甲) | XA10BFA025A001010205521 | NHSA |
| 双鹤天安药业(贵州)股份有限公司 | 国药准字H20223652 | 50mg | Category A (甲) | XA10BFA025A001010205530 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20223062 | 50mg | Category A (甲) | XA10BFA025A001010206632 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20213222 | 50mg | Category A (甲) | XA10BFA025A001010280081 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010281767 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20213876 | 50mg | Category A (甲) | XA10BFA025A001010283198 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010283544 | NHSA |
| 恒昌(广州)新药研究有限公司 | 国药准字H20253463 | 50mg | Category A (甲) | XA10BFA025A001010283569 | NHSA |
| 山东普瑞曼药业有限公司 | 国药准字H20255254 | 50mg | Category A (甲) | XA10BFA025A001010284621 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001010300062 | NHSA |
| 华润赛科药业有限责任公司 | 国药准字H20223141 | 50mg | Category A (甲) | XA10BFA025A001010300111 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20193360 | 50mg | Category A (甲) | XA10BFA025A001010300177 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20223134 | 50mg | Category A (甲) | XA10BFA025A001010301066 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010302770 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20153002 | 100mg | Category A (甲) | XA10BFA025A001010304520 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010304658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010304960 | NHSA |
| 贵州圣济堂制药有限公司 | 国药准字H20213948 | 50mg | Category A (甲) | XA10BFA025A001010305521 | NHSA |
| 双鹤天安药业(贵州)股份有限公司 | 国药准字H20223652 | 50mg | Category A (甲) | XA10BFA025A001010305530 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20223062 | 50mg | Category A (甲) | XA10BFA025A001010306632 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20213222 | 50mg | Category A (甲) | XA10BFA025A001010380081 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010381767 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20213876 | 50mg | Category A (甲) | XA10BFA025A001010383198 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010383544 | NHSA |
| 恒昌(广州)新药研究有限公司 | 国药准字H20253463 | 50mg | Category A (甲) | XA10BFA025A001010383569 | NHSA |
| 山东普瑞曼药业有限公司 | 国药准字H20255254 | 50mg | Category A (甲) | XA10BFA025A001010384621 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001010400062 | NHSA |
| 华润赛科药业有限责任公司 | 国药准字H20223141 | 50mg | Category A (甲) | XA10BFA025A001010400111 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20193360 | 50mg | Category A (甲) | XA10BFA025A001010400177 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20223134 | 50mg | Category A (甲) | XA10BFA025A001010401066 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010402770 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20153002 | 100mg | Category A (甲) | XA10BFA025A001010404520 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010404658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010404960 | NHSA |
| 双鹤天安药业(贵州)股份有限公司 | 国药准字H20223652 | 50mg | Category A (甲) | XA10BFA025A001010405530 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20223062 | 50mg | Category A (甲) | XA10BFA025A001010406632 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20213222 | 50mg | Category A (甲) | XA10BFA025A001010480081 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010481767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010483544 | NHSA |
| 山东普瑞曼药业有限公司 | 国药准字H20255254 | 50mg | Category A (甲) | XA10BFA025A001010484621 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001010500062 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20193360 | 50mg | Category A (甲) | XA10BFA025A001010500177 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20223134 | 50mg | Category A (甲) | XA10BFA025A001010501066 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010502770 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010504658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010504960 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20223062 | 50mg | Category A (甲) | XA10BFA025A001010506632 | NHSA |
| 乐普制药科技有限公司 | 国药准字H20213222 | 50mg | Category A (甲) | XA10BFA025A001010580081 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010581767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010583544 | NHSA |
| 山东普瑞曼药业有限公司 | 国药准字H20255254 | 50mg | Category A (甲) | XA10BFA025A001010584621 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001010600062 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20193360 | 50mg | Category A (甲) | XA10BFA025A001010600177 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20223134 | 50mg | Category A (甲) | XA10BFA025A001010601066 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010602770 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010604658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010604960 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20223062 | 50mg | Category A (甲) | XA10BFA025A001010606632 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010681767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010683544 | NHSA |
| 山东普瑞曼药业有限公司 | 国药准字H20255254 | 50mg | Category A (甲) | XA10BFA025A001010684621 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001010700062 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20193360 | 50mg | Category A (甲) | XA10BFA025A001010700177 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010702770 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010704658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010704960 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010781767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010783544 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20203314 | 50mg | Category A (甲) | XA10BFA025A001010802770 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010804658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010804960 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010881767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010883544 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244563 | 50mg | Category A (甲) | XA10BFA025A001010904658 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001010904960 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001010981767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001010983544 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001011004960 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011081767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001011083544 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001011104960 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011181767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001011183544 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213032 | 50mg | Category A (甲) | XA10BFA025A001011204960 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011281767 | NHSA |
| 石家庄市华新药业有限责任公司 | 国药准字H20256190 | 50mg | Category A (甲) | XA10BFA025A001011283544 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001011981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012081767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012181767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012281767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001012981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013081767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013181767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013281767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001013981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014081767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014181767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014281767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001014981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213661 | 50mg | Category A (甲) | XA10BFA025A001015081767 | NHSA |
| 拜耳医药保健有限公司 | 国药准字H19990205 | 50mg | Category A (甲) | XA10BFA025A001020100002 | NHSA |
| 北京博康健基因科技有限公司 | 国药准字H20203562 | 50mg | Category A (甲) | XA10BFA025A001020100024 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001020100062 | NHSA |
| 重庆药友制药有限责任公司 | 国药准字H20223135 | 100mg | Category A (甲) | XA10BFA025A001020101066 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20020202 | 50mg | Category A (甲) | XA10BFA025A001020104520 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203311 | 50mg | Category A (甲) | XA10BFA025A001020104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20244564 | 100mg | Category A (甲) | XA10BFA025A001020104658 | NHSA |
| 贵州圣济堂制药有限公司 | 国药准字H20213948 | 50mg | Category A (甲) | XA10BFA025A001020105521 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20237040 | 0.1g | Category A (甲) | XA10BFA025A001020106632 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020181767 | NHSA |
| 拜耳医药保健有限公司 | 国药准字H19990205 | 50mg | Category A (甲) | XA10BFA025A001020200002 | NHSA |
| 北京博康健基因科技有限公司 | 国药准字H20203562 | 50mg | Category A (甲) | XA10BFA025A001020200024 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20020202 | 50mg | Category A (甲) | XA10BFA025A001020204520 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203311 | 50mg | Category A (甲) | XA10BFA025A001020204641 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20237040 | 0.1g | Category A (甲) | XA10BFA025A001020206632 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020281767 | NHSA |
| 拜耳医药保健有限公司 | 国药准字H19990205 | 50mg | Category A (甲) | XA10BFA025A001020300002 | NHSA |
| 北京博康健基因科技有限公司 | 国药准字H20203562 | 50mg | Category A (甲) | XA10BFA025A001020300024 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20020202 | 50mg | Category A (甲) | XA10BFA025A001020304520 | NHSA |
| 江苏德源药业股份有限公司 | 国药准字H20237040 | 0.1g | Category A (甲) | XA10BFA025A001020306632 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020381767 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20020202 | 50mg | Category A (甲) | XA10BFA025A001020404520 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020481767 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20020202 | 50mg | Category A (甲) | XA10BFA025A001020504520 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020581767 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20020202 | 50mg | Category A (甲) | XA10BFA025A001020604520 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020681767 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20020202 | 50mg | Category A (甲) | XA10BFA025A001020704520 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001020981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021081767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021181767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021281767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001021981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022081767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022181767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022281767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001022981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023081767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023181767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023281767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001023981767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024081767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024181767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024281767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024381767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024481767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024581767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024681767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024781767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024881767 | NHSA |
| 辽宁鑫善源药业有限公司 | 国药准字H20213662 | 100mg | Category A (甲) | XA10BFA025A001024981767 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001030100062 | NHSA |
| 杭州中美华东制药有限公司 | 国药准字H20153002 | 100mg | Category A (甲) | XA10BFA025A001030104520 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20227010 | 100mg | Category A (甲) | XA10BFA025A001030104641 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20227010 | 100mg | Category A (甲) | XA10BFA025A001030204641 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20227010 | 100mg | Category A (甲) | XA10BFA025A001030304641 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H20233870 | 50mg | Category A (甲) | XA10BFA025A001040100062 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 3 filings and 2 distinct first applicants.
Generic 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 北京双鹭药业股份有限公司 | CYHS2601716 | Generic | 2026/07/17 | Not stated by source | CDE |
| 北京双鹭药业股份有限公司 | CYHS2601715 | Generic | 2026/07/17 | Not stated by source | CDE |
| 天地恒一制药股份有限公司 | CYHS2602591 | Generic | 2026/10/22 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 北京双鹭药业股份有限公司 | CYHS2601716 | Generic | 2026/07/17 | Not stated by source | CDE |
| 北京双鹭药业股份有限公司 | CYHS2601715 | Generic | 2026/07/17 | Not stated by source | CDE |
| 天地恒一制药股份有限公司 | CYHS2602591 | Generic | 2026/10/22 | Not stated by source | CDE |
API registrations
Non-component matches: 14 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 阿卡波糖 | 玉星生物（集团）股份有限公司 | Y20240000315 | A | Exact ingredient | 2026/09/01 | CDE |
| 阿卡波糖 | 新宇药业股份有限公司 | Y20220000593 | A | Exact ingredient | 2026/07/21 | CDE |
| 阿卡波糖 | 山东鲁抗医药股份有限公司 | Y20220000409 | A | Exact ingredient | 2026/05/20 | CDE |
| 阿卡波糖 | 国药集团威奇达药业有限公司 | Y20220000197 | A | Exact ingredient | 2024/01/17 | CDE |
| 阿卡波糖 | 海正药业（杭州）有限公司 | Y20210000915 | A | Exact ingredient | 2023/02/03 | CDE |
| 阿卡波糖 | 丽珠集团福州福兴医药有限公司 | Y20210000114 | A | Exact ingredient | 2022/12/29 | CDE |
| 阿卡波糖 | 杭州中美华东制药江东有限公司 | Y20200001403 | A | Exact ingredient | 2026/10/23 | CDE |
| 阿卡波糖 | Bayer Pharma AG | Y20190009956 | A | Exact ingredient | — | CDE |
| 阿卡波糖 | CKD Bio Corporation | Y20190009952 | A | Exact ingredient | 2023/07/27 | CDE |
| 阿卡波糖 | CKD Bio Corporation | Y20190009951 | A | Exact ingredient | 2025/02/19 | CDE |
| 阿卡波糖 | 杭州中美华东制药有限公司 | Y20190009480 | A | Exact ingredient | — | CDE |
| 阿卡波糖 | 石药集团圣雪葡萄糖有限责任公司 | Y20190009389 | A | Exact ingredient | 2024/07/20 | CDE |
| 阿卡波糖 | 浙江海正药业股份有限公司 | Y20190008441 | A | Exact ingredient | 2024/08/02 | CDE |
| 阿卡波糖 | 丽珠集团新北江制药股份有限公司 | Y20190006488 | A | Exact ingredient | 2026/06/17 | CDE |
| 阿卡波糖 | 河北华荣制药有限公司 | Y20190000244 | I | Exact ingredient | 2019/05/17 | CDE |
| 阿卡波糖 | CKD Bio Corporation | Y20190000184 | A | Exact ingredient | 2024/10/08 | CDE |
| 阿卡波糖 | 杭州中美华东制药有限公司 | Y20170001909 | A | Exact ingredient | 2022/11/15 | CDE |
| 阿卡波糖 | Bayer AG | Y20170001896 | A | Exact ingredient | 2025/09/28 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/22Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Acarbose Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy